A two-center retrospective cohort study published in Clinical Rheumatology evaluated the prognostic significance of serum ferritin for predicting major adverse cardiovascular events (MACEs) in patients with Takayasu arteritis (TAK), where its clinical role has remained unclear. The study included 189 treatment-naïve patients with TAK who were followed for a median duration of 34 months. During follow-up, 37 patients (19.6%) experienced MACEs.
Patients with elevated baseline serum ferritin levels (cut-off value: 68.6 μg/L) had significantly higher MACE rates at 12, 36, 60, and 96 months compared with those with lower ferritin levels. Serum ferritin was identified as an independent predictor of MACEs at 96 months when analyzed as both a continuous variable (HR: 1.003; 95% CI: 1.001–1.006; P=0.007) and categorical variable (HR: 2.609; 95% CI: 1.280–5.320; P=0.008). Its predictive value…
